This system is designed for Type 1 and Type 2 diabetics 18 and older and will be the first continuous glucose monitoring system to offer a full year of sensor use, according to a Sept. 17 news release from Senseonics.
Eversense 365 has been cleared as an integrated CGM system that can integrate with compatible medical devices, including insulin pumps, as part of an automated insulin delivery system.
Ascensia expects to initiate the U.S. launch of the sensor in the fourth quarter of 2024, the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
